Abstract
Traditionally, the clinical endpoints used to monitor clinical trials in multiple sclerosis (MS) are the occurrence of relapses (usually expressed as a rate over time), and the degree of disability, most commonly evaluated using the Expanded Disability Status Scale (EDSS) [1].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452
McFarland H, Barkhof F, Antel J, Miller DH (2002) The role of MRI as a surrogate outcome measure in MS. Mult Scler 8:40–51
Prentice RL (1989) Surrogate markers in clinical trials: definition and operational criteria. Stat Med 8:431–440
Sormani MP, Bruzzi P, Comi GC, Filippi M (2002) MRI metrics as surrogate markers for clinical relapse rate in relapsing remitting MS patients. Neurology 58:417–421
Sormani MP, Bruzzi P, Beckmann K et al (2003) MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFNβ-lb. Neurology 60:1462–1466
Comi G, Filippi M, Wolinsky JS and the European/Canadian Glatiramer Acetate Study Group (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 49:290–297
Kappos L, Polman C, Pozzilli C et al (2001) Final analysis of the European multicenter trial on IFNβ-lb in secondary-progressive MS. Neurology 57:1969–1975
Li DKB, Zhao GJ, Paty DW and the University of British Columbia MS/MRI Analysis Research Group and the SPECTRIMS Study Group (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 56:1505–1513
Cohen JA, Citter GR, Goodman DA et al (2002) Benefit of interferon β-la on MSFC progression in secondary progressive MS. Neurology 59:679–687
Panitch H, Miller A, Paty D, Weinshenker B for the North American Study Group on Interferon beta-1b in Secondary Progressive MS (2004) Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63:1788–1795
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Italia
About this chapter
Cite this chapter
Sormani, M.P., Filippi, M. (2007). Validation of MRI Surrogates. In: Filippi, M., Rovaris, M., Comi, G. (eds) Neurodegeneration in Multiple Sclerosis. Topics in Neuroscience. Springer, Milano. https://doi.org/10.1007/978-88-470-0391-0_10
Download citation
DOI: https://doi.org/10.1007/978-88-470-0391-0_10
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0390-3
Online ISBN: 978-88-470-0391-0
eBook Packages: MedicineMedicine (R0)